Josef S Smolen Selected Research

Neoplasms (Cancer)

1/2023	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
1/2023	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
6/2020	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
1/2019	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
1/2019	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
6/2017	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
11/2016	Safety and efficacy of biosimilars in oncology.
10/2012	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.
6/2010	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josef S Smolen Research Topics

Disease

189	Rheumatoid Arthritis 11/2023 - 03/2002
45	Arthritis (Polyarthritis) 03/2024 - 01/2002
44	Necrosis 12/2023 - 04/2003
39	Psoriatic Arthritis 03/2024 - 07/2002
27	Inflammation (Inflammations) 01/2023 - 03/2002
24	Infections 01/2023 - 11/2004
24	Rheumatic Diseases (Rheumatism) 01/2021 - 01/2007
22	Pain (Aches) 12/2023 - 11/2002
20	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 01/2002
9	Neoplasms (Cancer) 01/2023 - 06/2010
9	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 03/2002
8	Herpes Zoster 01/2023 - 01/2019
8	Ankylosing Spondylitis 01/2022 - 07/2002
7	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024 - 11/2012
7	Lupus Nephritis 10/2023 - 10/2004
7	Fatigue 12/2020 - 03/2012
6	Disease Progression 12/2023 - 11/2002
6	Synovitis 12/2023 - 01/2008
6	Joint Diseases (Joint Disease) 01/2020 - 04/2003
6	Bone Resorption 01/2010 - 07/2002
5	COVID-19 02/2023 - 01/2022
5	Pneumonia (Pneumonitis) 01/2017 - 11/2004
4	Connective Tissue Diseases (Connective Tissue Disease) 01/2023 - 12/2007
4	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2023 - 04/2013
4	Osteoarthritis 01/2022 - 09/2007
4	Systemic Scleroderma (Systemic Sclerosis) 01/2022 - 08/2005
4	Chronic Disease (Chronic Diseases) 09/2019 - 01/2017
3	Cytokine Release Syndrome 01/2023 - 01/2022
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 11/2009
3	Proteinuria 01/2020 - 10/2004
3	Nephritis 01/2017 - 10/2004
3	Mixed Connective Tissue Disease (MCTD) 07/2011 - 08/2005
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2023 - 11/2023
2	Axial Spondyloarthritis 12/2023 - 01/2023
2	Atopic Dermatitis (Atopic Eczema) 11/2023 - 11/2020
2	Body Weight (Weight, Body) 10/2023 - 01/2019

Drug/Important Bio-Agent (IBA)

57	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 10/2004
47	Antirheumatic Agents (DMARD)IBA 03/2024 - 04/2002
29	Adalimumab (Humira)FDA Link 01/2023 - 04/2003
28	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2023 - 03/2002
26	Infliximab (Remicade)FDA Link 01/2023 - 10/2004
22	baricitinibIBA 01/2023 - 01/2014
21	GlucocorticoidsIBA 08/2023 - 02/2005
20	Tumor Necrosis Factor InhibitorsIBA 03/2023 - 01/2003
20	AutoantibodiesIBA 01/2023 - 03/2002
19	tocilizumab (atlizumab)FDA Link 01/2023 - 12/2007
18	CytokinesIBA 12/2023 - 11/2002
18	Biosimilar PharmaceuticalsIBA 01/2023 - 03/2013
17	Etanercept (Enbrel)FDA Link 01/2023 - 05/2005
14	tofacitinibIBA 01/2023 - 01/2014
14	C-Reactive ProteinIBA 01/2022 - 07/2002
12	Rituximab (Mabthera)FDA Link 01/2023 - 07/2007
12	Abatacept (Orencia)FDA Link 01/2023 - 07/2007
11	Leflunomide (Arava)FDA LinkGeneric 01/2023 - 06/2004
11	Interleukin-6 (Interleukin 6)IBA 01/2023 - 03/2008
11	golimumab FDA Link 01/2023 - 07/2009
10	Ustekinumab (CNTO 1275)FDA Link 10/2023 - 09/2015
10	ametantrone (HAQ)IBA 10/2023 - 04/2007
10	Janus Kinase InhibitorsIBA 01/2023 - 01/2017
10	Certolizumab Pegol FDA Link 01/2023 - 11/2009
9	AntibodiesIBA 01/2021 - 08/2005
7	InterleukinsIBA 03/2024 - 06/2012
6	Biomarkers (Surrogate Marker)IBA 12/2023 - 07/2002
6	Interleukin-12 (IL 12)IBA 01/2023 - 01/2005
6	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2023 - 06/2004
6	Monoclonal AntibodiesIBA 12/2022 - 11/2004
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 02/2006
6	Janus KinasesIBA 10/2020 - 06/2017
6	Rheumatoid FactorIBA 01/2018 - 11/2002
5	upadacitinibIBA 01/2023 - 12/2016
5	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 12/2022 - 12/2007
5	apremilastIBA 01/2022 - 01/2014
5	ixekizumabIBA 01/2022 - 01/2020
5	Prostaglandins AIBA 01/2020 - 09/2012
5	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2020 - 01/2005
4	Interleukin-1 (Interleukin 1)IBA 07/2022 - 12/2003
4	secukinumabIBA 01/2020 - 09/2015
4	ElementsIBA 08/2017 - 08/2007
4	CollagenIBA 01/2015 - 07/2002
4	AutoantigensIBA 12/2007 - 03/2002
4	OsteoprotegerinIBA 02/2004 - 03/2002
3	EnzymesIBA 11/2023 - 06/2004
3	omega-Chloroacetophenone (Mace)IBA 01/2023 - 01/2019
3	sarilumabIBA 01/2023 - 06/2017
3	amsonic acid (DAS)IBA 01/2020 - 11/2012
3	Anti-Citrullinated Protein AntibodiesIBA 01/2018 - 09/2010
3	pristane (pristan)IBA 01/2017 - 12/2007
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 05/2008
3	Immunoglobulins (Immunoglobulin)IBA 06/2011 - 12/2007
3	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 01/2006 - 07/2002
2	Interleukin-23 (Interleukin 23)IBA 12/2023 - 05/2017
2	Phosphates (Orthophosphate)IBA 12/2023 - 07/2004
2	ChemokinesIBA 11/2023 - 01/2019
2	ImmunosorbentsIBA 11/2023 - 01/2021
2	Messenger RNA (mRNA)IBA 11/2023 - 12/2022
2	belimumabIBA 10/2023 - 02/2015
2	Tacrolimus (Prograf)FDA LinkGeneric 10/2023 - 01/2020

Therapy/Procedure

104	Therapeutics 03/2024 - 01/2002
6	Aftercare (After-Treatment) 11/2018 - 07/2009
3	Drug Therapy (Chemotherapy) 03/2012 - 07/2004